



Ziopharm Oncology Presenting at the 37th Annual J.P. Morgan Healthcare Conference

January 10, 2019

BOSTON, MA, January 10, 2019 (GLOBE NEWSWIRE) -- [Ziopharm Oncology](#), Inc. (Nasdaq:ZIOP)

Laurence Cooper, M.D., Ph.D., Chief Executive Officer, today is presenting at the 37th Annual J.P. Morgan Healthcare Conference in San Francisco at 9 a.m. PT/12 noon ET.

To access a live audio webcast or replay of the presentation, visit: <https://jpmorgan.metameetings.net/events/healthcare19/sessions/24078-ziopharm-oncology/webcast>

To access the live Q&A session or a replay, visit: <https://jpmorgan.metameetings.net/events/healthcare19/sessions/24127-ziopharm-oncology-q-a/webcast>

About Ziopharm Oncology, Inc.

Ziopharm Oncology is an immuno-oncology company focused on developing end-to-end cost-effective solutions using its non-viral *Sleeping Beauty* platform for TCR and CAR T-cell therapy and immune-stimulating gene therapy with Controlled interleukin 12 (IL-12). The *Sleeping Beauty* platform genetically modifies T cells with DNA plasmids to express T-cell receptors (TCRs) to target specific antigens in solid tumors and chimeric antigen receptors (CARs) to target CD19 in blood cancers with the Company's very rapid T-cell manufacturing process. The *Sleeping Beauty* platform is being advanced in collaboration with the National Cancer Institute, The University of Texas MD Anderson Cancer Center and Eden BioCell. The Company also is developing its Controlled IL-12 platform or Ad-RTS-hIL-12 plus veledimex as monotherapy and in combination with immune checkpoint inhibitors to treat brain cancer, including a collaboration with Regeneron Pharmaceuticals.

Company contacts:

David Connolly

Vice President, Corporate Communications and Investor Relations

617-502-1881

dconnolly@ziopharm.com

Mike Moyer

Vice President, Portfolio Strategy

617-765-3770

mmoyer@ziopharm.com